A Coordinated Effort to Accelerate Approvals
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have launched a new initiative inviting early adopters to trial an accelerated and aligned pathway for new treatments. The move is part of the UK government’s broader effort to streamline regulation, strengthen the life sciences sector and deliver innovative medicines to patients more quickly.
Traditionally, medicine approval in the UK has been a two-step process: the MHRA first assesses and authorises a product for market, and NICE then conducts a health technology assessment to evaluate its cost-effectiveness for the National Health Service (NHS). The new aligned pathway will bring these two stages together, allowing regulatory authorisation and value assessment to take place in parallel.
This marks the first time that both agencies will publish their decisions simultaneously, cutting months off the usual process and ensuring patients can benefit sooner from cutting-edge treatments.
How the Aligned Pathway Works
The initiative aims to create a seamless system where the MHRA and NICE collaborate early in the product development process. Companies seeking access to the pathway are encouraged to engage with regulators as soon as possible and to list their products on the UK PharmaScan database at least three years before their expected authorisation date.
Through joint scientific advice, the MHRA and NICE will guide companies on both regulatory and health economic evidence requirements, reducing duplication and uncertainty. From April 2026, a fully integrated advice service will provide a single point of contact for pharmaceutical developers.
Early engagement will enable regulators to assess safety, efficacy and value concurrently, leading to faster publication of coordinated decisions and accelerating patient access to innovative therapies.
According to NICE’s Ten Year Health Plan for the NHS, patients in England could receive eligible new medicines between three and six months sooner under the new pathway.
Benefits for Industry, Patients and the NHS
For pharmaceutical companies, the aligned pathway promises a more predictable and efficient route to market. By synchronising regulatory and health technology assessments, it helps developers plan commercial launches and NHS access strategies in a coordinated manner.
For the NHS, the initiative will reduce delays in adopting new treatments, improving patient outcomes and relieving pressure on health services. Patients will ultimately benefit from earlier access to innovative therapies, particularly for conditions with limited treatment options.
The collaboration also enhances the UK’s position as a global hub for life sciences innovation. Streamlined regulation and faster patient access make the UK more attractive for clinical research and early product launches, supporting wider economic growth in the sector.
Balancing Speed with Rigour
While the aligned pathway is designed to accelerate access, both the MHRA and NICE stress that it will not compromise on safety or scientific standards. The same stringent evidence requirements for quality, safety and efficacy will apply, with the added benefit of earlier regulatory and HTA alignment.
Experts also highlight the importance of maintaining transparency and independence throughout the process. The agencies have confirmed that all decisions will continue to follow their established frameworks and be published for public review.
However, success will depend on effective coordination and readiness from participating companies. The compressed timelines mean that developers must prepare evidence packages earlier and engage proactively with regulators. Those unprepared for the new model may face challenges meeting the tighter schedules.
Part of a Wider UK Reform Agenda
The aligned pathway sits within the government’s broader regulatory modernisation strategy, which includes the Innovative Licensing and Access Pathway (ILAP). ILAP already enables companies developing transformative therapies to engage early with regulators and health authorities, ensuring that promising treatments reach patients at the earliest safe opportunity.
Together, ILAP and the new aligned pathway represent a major step forward in the UK’s ambition to position itself as a global leader in medicine development and patient access. These reforms are also central to the government’s Life Sciences Sector Vision, which aims to make the UK the best place to test, approve and deploy medical innovations.
The initiative is supported by the NHS Accelerated Access Collaborative, which works to ensure the NHS adopts new technologies efficiently. As the pilot progresses, MHRA and NICE will work closely with early adopters to refine the process. Feedback from participating companies will shape how the aligned pathway operates when it becomes fully implemented in the coming years.
Looking Ahead
If successful, the pilot could become the standard route for bringing new medicines to NHS patients, setting a precedent for more agile and collaborative regulation across Europe and beyond. The initiative demonstrates a clear shift toward a system that prioritises both innovation and timely patient benefit, without compromising scientific integrity.
By reducing delays and integrating decision-making, the aligned pathway could redefine how new medicines move from laboratory research to the hands of clinicians and patients across the UK.
